Shares of Eli Lilly plummeted 14% on Thursday, pacing what would be the stock’s largest loss in decades after the pharmaceutical giant unveiled data for its obesity treatment pill that fell behind ...
In an Aug. 7 earnings call, Eli Lilly CEO David Ricks told investors that the company plans to submit the drug, orforglipron, to the FDA for approval by the end of the year. Dan Skovronsky, chief ...
Eli Lilly continues to establish its dominance in the growing market for GLP-1 therapies. The company's oral candidate for diabetes treatment and weight loss looks very promising. Even after soaring ...
Hosted on MSN
Eli Lilly to build $6.5 billion Texas manufacturing facility for obesity pill, other drugs
Eli Lilly said it will spend $6.5 billion to build a manufacturing facility in Houston, Texas, to boost production of the company's pipeline of small molecule drugs, including its closely watched ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback